Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Portfolio Pulse from
Biogen (BIIB) is facing declining revenues due to competitive pressures on its key multiple sclerosis drugs and spinal muscular atrophy treatment. The company's total revenues fell by 2% in 2024.
March 14, 2025 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen's revenue has declined by 2% in 2024 due to competitive pressures on its multiple sclerosis and spinal muscular atrophy drugs. The company is looking to new drugs to potentially revive growth.
The decline in Biogen's revenue is directly linked to competitive pressures on its key drugs, which is a significant concern for investors. The company's future growth may depend on the success of new drugs, but the current impact is negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100